Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$8.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 422.13% year-over-year to -$8.7 million; the TTM figure through Mar 2026 stood at -$6.4 million (down 187.74% YoY), while the FY2025 annual figure was $5.0 million, down 58.4% from the prior year.
• Net Income towards Common Stockholders retreated to -$8.7 million in Q1 2026 per GYRE's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $51.6 million in Q2 2022 and bottomed at -$101.0 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$4.8 million across 5 years, with a median of $1.1 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 359.09% — and 2025, when it sank 1640.4%.
• Gyre Therapeutics' Net Income towards Common Stockholders stood at -$29.9 million in 2022, then plunged by 237.7% to -$101.0 million in 2023, then surged by 99.9% to -$99000.0 in 2024, then tumbled by 1640.4% to -$1.7 million in 2025, then slumped by 404.41% to -$8.7 million in 2026.
• Business Quant data shows GYRE's Net Income towards Common Stockholders at -$8.7 million in Q1 2026, -$1.7 million in Q4 2025, and $3.6 million in Q3 2025.